Menssana Research is the leading developer of advanced new breath tests for detection of disease.
Early detection of diseases can often bring great benefits. Some cancers can be completely eradicated if they are detected early and treated promptly, but this may require invasive testing that is often expensive. For example, biopsies may be painful and x-rays are potentially harmful. The challenge to modern medicine is to develop non-invasive tests which can detect diseases without causing pain or damage to the body, and cost less.
Breath testing is probably the least invasive of all diagnostic tests. Even people who are elderly or incapacitated can generally donate a breath sample without inconvenience. But chemical analysis of breath is technically very difficult, which is why breath testing has played only a minor role in medical diagnosis until recently.
Menssana Research has developed the BreathX breath test provides a rapid and cost-effective new tool for disease screening.
Michael Phillips MD FACP.is founder and chief executive officer of Menssana Research, Inc. He is also Professor of Clinical Medicine at New York Medical College, Valhalla, New York, as well as a member of the Royal College of Physicians in the UK.